Principal Financial Group Inc Nurix Therapeutics, Inc. Transaction History

Principal Financial Group Inc

  • $160 Billion
  • Q2 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024
SELL
$7.77 - $15.66 $9,184 - $18,510
-1,182 Reduced 8.36%
12,953 $190,000
Q4 2023

Feb 07, 2024
SELL
$4.25 - $10.71 $5,933 - $14,951
-1,396 Reduced 8.99%
14,135 $145,000
Q3 2023

Nov 02, 2023
BUY
$7.86 - $10.08 $15,735 - $20,180
2,002 Added 14.8%
15,531 $122,000
Q2 2023

Aug 07, 2023
BUY
$8.7 - $13.28 $6,307 - $9,628
725 Added 5.66%
13,529 $135,000
Q1 2023

May 09, 2023
BUY
$8.56 - $13.26 $15,348 - $23,775
1,793 Added 16.28%
12,804 $113,000
Q4 2022

Feb 09, 2023
BUY
$9.86 - $14.59 $108,568 - $160,650
11,011 New
11,011 $120,000

Others Institutions Holding NRIX

# of Institutions
183
Shares Held
66.4M
Call Options Held
40.9K
Put Options Held
106K
View Full List

About Nurix Therapeutics, Inc.

NRIX Quotes by TradingView
  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1.04B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email